-Issues related to FDA review of active ingredients in over-the-counter products
-Issues related to Generally Recognized as Safe (GRAS) and Additive Ingredients Regulation -H.R. 1219, Oral Health Products Inclusion Act -Issues related to New Approach Methodologies (NAMs) non-animal technologies used to evaluate drug safety and efficacy
-Section 232 Steel/Aluminum Trade Investigation -Issues Related to the Review of the US-Mexico-Canada Trade Agreement (No Bill) -Section 122 Balance of Payment Tariffs -Section 301 Excess Capacity/Forced Labor Investigations -Medical Devices/PPE Section 232 Investigation -U.S.-China Board of Trade -Industrial Machinery Section 232 Investigation -Issues related to counterfeit products/illicit trade
-Issues Related to Product Safety and Quality Assurance (No Bill) -Issues related to Labeling of Menstrual Products -PACK Act (Packaging and Claims Knowledge Act) HR 6832
-Implementation of Cybersecurity Reporting Law -Issues related to Toxic Substances Control Act Reform -Safer Choice Program Authorization Act (S. 4664)
-H.R. 2269/S. 1092 - Wastewater Infrastructure Pollution Prevention and Environmental Safety (WIPPES) Act -Recycled Materials Attribution Act (RMAA) HR 7502 -Issues related to sustainability
-OECD Digital Tax Project (Global Minimum Tax Implementation) -Implementation of H.R. 1 - One Big Beautiful Bill Act (Corporate/International Provisions) -OECD Digital Tax Project (Reallocation of Global Taxing Rights) -Ongoing Negotiations of US Bilateral Tax Treaties -Oral Health Products Inclusion Act (H.R. 1219)
-Issues related to the SHIP IT Act